Clinical trial
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With…
NCT00117143 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00117143 |
|---|---|
| Title | Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) |
| Official title | An Open-label, Unit Dose-finding Study Evaluating the Safety and Efficacy of Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Thrombocytopenic Purpura |
| Intervention type | Drug |
| Interventions | Romiplostim |
| Enrollment | 16 |
| Start date | Dec 2, 2002 |
| Primary completion | Jul 19, 2004 |
| Completion | Jul 19, 2004 |
| First posted | Jul 4, 2005 |
| Last update posted | Jun 26, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: